Moreover, subcutaneous treatment with celastrol was found to attenuate the accumulation of pathological plaque and microglial activation in the double transgenic Tg PS1/APPsw (human APP695sw mutation and the presenilin-1 mutation M146L) AD mice (Paris et al., 2010). This evidence concerns the gene PSEN1 and Alzheimer disease.